Dear Doctor Letter (Rote-Hand-Brief) on Sutent®: Possible risk of osteonecrosis of the jaw
2010.12.10
Active substance: sunitinibe
Important safety-relevant information on the potential risk of osteonecrosis of the jaw in cancer patients treated with sunitinibe (Sutent®) associated with concomitant or previous administration of bisphosphonates.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN